Ireland's doctors notified over suspension of Reductil
Abbott Laboratories Ireland has issued an important safety information notice to doctors on the suspension of marketing authorisations for sibutramine (Reductil), due to increased cardiovascular risk observed in the SCOUT trial.
The notice from Abbott's Medical Director Dr Michelle Costello-Smith advised prescribers that they should not issue any further prescriptions for the weight-loss medication, and should review the treatment of patients currently taking the obesity drug.
Read the full article here.
